Test Sierologici Sars Cov2 Lexo

Human anti-SARS-CoV2(N) IgG ELISA Kit

EKF60809-48T 48T
EUR 400.4

Human IgG antibody Laboratories manufactures the test sierologici sars cov2 lexo reagents distributed by Genprice. The Test Sierologici Sars Cov2 Lexo reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Test. Other Test products are available in stock. Specificity: Test Category: Sierologici Group: Sars Cov2

Human anti-SARS-CoV2 (S) IgG ELISA Kit

10x96-Strip-Wells
EUR 3900

Human anti-SARS-CoV2 (S) IgG ELISA Kit

48-Strip-Wells
EUR 340

Human anti-SARS-CoV2 (S) IgG ELISA Kit

5x96-Strip-Wells
EUR 2045

Human anti-SARS-CoV2 (S) IgG ELISA Kit

96-Strip-Wells
EUR 455

SARS-COV2 RBD IgG Titer ELISA Kit

  • Ask for price
  • Ask for price
  • 1 Kit
  • 1 Kit

SARS-CoV2-N Antibody

N/A
EUR 276.5
Description: N/A

SARS-CoV2-N Antibody

N/A
EUR 276.5
Description: N/A

Sars Cov2 information

SARS CoV2 Spike S1 Antibody (Clone: ABM3D6.1G6)(13-33aa)

MBS669600-5x01mg 5x0.1mg
EUR 1990

SARS CoV2 Spike S1 Antibody (Clone: ABM4A10.1D3)(239-257aa)

MBS669599-0025mg 0.025mg
EUR 225

SARS CoV2 Spike S1 Antibody (Clone: ABM4A10.1D3)(239-257aa)

MBS669599-01mg 0.1mg
EUR 445

SARS CoV2 Spike S1 Antibody (Clone: ABM4A10.1D3)(239-257aa)

MBS669599-5x01mg 5x0.1mg
EUR 1990

SARS COV2 Spike protein S Recombinant-Fc (AVI tag)

MBS553732-01mg 0.1mg
EUR 490

SARS COV2 Spike protein S Recombinant-Fc (AVI tag)

MBS553732-05mg 0.5mg
EUR 1570

anti- SARS antibody

FNab07609 100µg
EUR 658.5
Description: Antibody raised against SARS

SARS-CoV-2 Ag Rapid Test

HSGIA2200A1COV 20 Tests/Kit Ask for price
Description: The SARS-CoV-2 Ag Rapid Test is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens in nasal swab specimens from individualswith suspected SARS-CoV-2 infection in conjunction with clinical presentation and the results of other laboratory tests. Results are for the detection of SARS-CoV-2 Antigens. An antigen is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or coinfection with other viruses. The agent detected may not be the definite cause of disease. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions. Negative results should be treated as presumptive and confirmed with a molecular assay, if necessary for patient management. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19. The SARS-CoV-2 Ag Rapid Test is intended for use by self-testing personnel.

SARS-CoV2 RBD

0571-001 100 ug
EUR 493.75
Description: SARS-CoV-2 Receptor Binding Domain

SARS-CoV-2 Antigen Rapid Test

INCP-502H 25 Tests
EUR 8.75

SARS-CoV-2 Antigen Rapid Test Kit

abx294181-100g 100 µg
EUR 850

SARS-CoV-2 Antigen Rapid Test Kit

abx294181-20g 20 µg
EUR 100

SARS-CoV-2 Antigen Rapid Test Kit

abx294181-50g 50 µg
EUR 450

SARS-CoV-2 Antigen Rapid Test Kit

CoV2Ag-1 1T
EUR 9.6
Description: This kit adopts the sandwich method and the technical principle of colloidal gold immunochromatography to qualitative determine the SARS-CoV-2 antigen. During the test, the sample is dropped into the sample well, and chromatography is performed under the capillary effect. The SARS-CoV-2 antigen in the sample combined with the colloidal goldlabeled SARS-CoV-2 monoclonal antibody I, and then spread to the test area. It is captured by another coated antibody (SARS-CoV-2 monoclonal antibody II), to form a complex and gather in the test area (T line). The quality control area is coated with the goat antimouse antibody, and the colloidal gold-labeled antibody is captured to form a complex and aggregate in the quality control area (C line). If the C line does not show color, it indicates that the result is invalid, and this sample needs to be tested again.

SARS-CoV-2 Antigen Rapid Test Kit

CoV2Ag-25 25T/kit
EUR 42
Description: This product is used for in vitro qualitative detection of SARS-CoV-2 antigen in human oropharyngeal swabs, nasal swabs and nasopharyngeal swabs. It is helpful as an aid in the screening of early mild, asymptomatic, or acute patients for identification of SARS-CoV-2 infection.

SARS-CoV-2 Antigen Rapid Test Kit

GF101A2 25 Test/kit Ask for price

SARS-CoV-2 Rapid Antigen Test Nasal

9901-NCOV-03G 25 Tests/Kit
EUR 112.8
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke